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Abstract
Background: Ovarian cancer (OC) ascites consist in a proinflammatory tumor environment that is characterized by
the presence of various cytokines, chemokines and growth factors. The presence of these inflammatory-related
factors in ascites is associated with a more aggressive tumor phenotype. CCL18 is a member of CCL chemokines
and its expression has been associated with poor prognosis in some cancers. However, its role in OC progression
has not been established. Therefore, the aim of the current study was to elucidate the role of ascites CCL18 in OC
progression.
Methods: ELISA and tissue microarrays were used to assess CCL18 in ascites and phospho-Pyk2 expression in
cancer tissues respectively. Cell migration was assessed using Boyden chambers. CCL18 and ascites signaling was
examined in ovarian cancer cells utilizing siRNA and exogenous gene expression.
Results: Here, we show that CCL18 levels are markedly increased in advanced serous OC ascites relative to
peritoneal effusions from women with benign conditions. Ascites and CCL18 dose-dependently enhanced the
migration of OC cell lines CaOV3 and OVCAR3. CCL18 levels in ascites positively correlated with the ability of ascites
to promote cell migration. CCL18 blocking antibodies significantly attenuated ascites-induced cell migration. Ascites
and CCL18 stimulated the phosphorylation of proline-rich tyrosine kinase 2 (Pyk2) in CaOV3 and OVCAR3 cells. Most
importantly, the expression of phosphorylated Pyk2 in serous OC tumors was associated with shorter progression-
free survival. Furthermore, enforced expression of Pyk2 promoted tumor cell migration while siRNA-mediated
downregulation of Pyk2 attenuated cell migration. Downregulation of Pyk2 markedly inhibited ascites and
CCL18-induced cell migration.
Conclusions: Taken together, our findings establish an important role for CCL18, as a component of ascites, in the
migration of tumor cells and identify Pyk2 as prognostic factor and a critical downstream signaling pathway for
ascites-induced OC cell migration.
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Background
Ovarian cancer (OC) is the second most frequent
gynecological cancer and is associated with a poor prog-
nosis because OC progression is often asymptomatic
and is detected at a late stage. Widespread intraperito-
neal metastasis is the major cause of mortality among
OC patients [1, 2]. It results from a sequential process in
which tumor cells shed from the primary tumor into as-
cites are disseminated throughout the peritoneal cavity
[1, 2]. Most OC patients present with advanced diseases
(stage III/IV) with large amount of ascites. The presence
of ascites at diagnostic correlates with peritoneal spread
of the tumor and with a decreased 5-year survival rate
[3–5]. A variety of cytokines, chemokines and growth
factors are present in OC ascites [6–8]. There is growing
evidence that inflammatory cytokines/chemokines within
ascites lead to a state of chronic inflammation [9, 10].
Chronic inflammation, in turn, contributes to tumor
progression by creating a proliferative, migrating and
prosurvival environment [11, 12]. Indeed, OC ascites
have been shown to enhance tumor cell proliferation,
migration and survival [13–17].
Chemokines are important components of cancer-
related inflammation and, in the tumor environment,
may play a pivotal role in tumor progression and metas-
tasis. Chemokine (C-C motif ) ligand 18 (CCL18), which
is predominately produced by tumor-associated macro-
phages (TAMs), promote the migration and invasion of
breast cancer cells [18, 19]. CCL18 also correlates with
metastasis and poor prognosis of patients with breast can-
cer [20]. CCL18 is expressed at higher levels in OC ascites
compared to none ovarian carcinomas [21]. Its tissue ex-
pression correlates with metastasis in OC patients [22].
Serum levels of CCL18 has been examined as a potential
biomarker for discriminating patients with OC versus
those with benign gynecological conditions [23].
CCL18 effects on migration and invasion of breast
cancer cells are mediated by the proline-rich tyrosine
kinase 2 (Pyk2) [19]. Pyk2 is a cytoplasmic tyrosine kinase
that belongs to the focal adhesion kinase (FAK) family
[24]. CCL18 specifically binds PITPNM3/Nir1 receptor
and activates Pyk2 by phosphorylation of tyrosine residue
Y402 that functions as a docking site for the SH2 domain
of Src [25]. Pyk2 regulates different signal transduction
cascade that control cell proliferation, migration and inva-
sion [20, 22, 26, 27]. Pyk2 is overexpressed in hepatocellu-
lar carcinoma (HCC) cells and its expression is associated
with poor prognosis [25]. Enforced expression of Pyk2
promotes migration and invasion in HCC cells via the ac-
tivation of ERK pathway [27, 28]. Little is known however
about the role Pyk2 in OC cells.
In this study, we aim to investigate the contribution of
the tumor environment to CCL18/Pyk2 signaling and
the migration of OC cells. We demonstrate that high
levels of CCL18 are present in OC ascites and that CCL18
is an important component of ascites for the ascites-
mediated migration of OC cells. Ascites and CCL18
stimulate the phosphorylation and expression of Pyk2,
which is critical for mediated CCL18-induced migration.
Methods
Patients
Ascites are routinely obtained at the time of the debulk-
ing surgery of ovarian cancer patients treated at the
Centre Hospitalier Universitaire de Sherbrooke. After
collection, cell-free ascites are stored at −80 °C in our
tumor bank until use. The study population consisted of
53 women with newly diagnosed epithelial ovarian can-
cer admitted at the Centre Hospitalier Universitaire de
Sherbrooke. Twenty four cases with histologically be-
nign gynecological conditions including fibromas,
endometriosis, and mucinous and serous cystadeno-
mas constituted the control group. This study was ap-
proved by the Institutional Review Board of the
Centre de Recherche Étienne-Le Bel. Informed consent
was obtained from women that underwent surgery by the
gynecologic oncology service between 2000 and 2014. All
samples were reviewed by an experienced pathologist.
Baseline characteristics and serum CA125 levels were
collected for all patients. All patients had a follow up
≥12 months. Disease progression was defined by either
serum CA125 ≥2 X nadir value on two occasions, docu-
mentation of lesion progression or appearance of new
lesions on CT-scan or death. Patient’s conditions were
staged according to the criteria of the International Feder-
ation of Gynecology and Obstetrics (FIGO). PFS was de-
fined by the time from the initial surgery to evidence of
disease progression.
Cell culture and reagents
The human OC cell lines CaOV3 and OVCAR3 were
obtained from the American Type Culture Collection
(Manassas, VA) and maintained in a humidified 5 % CO2
incubator at 37 °C. Cells were passaged twice weekly.
OVCAR3 cells were maintained in RPMI-1640 (Wisent,
St-Bruno, QC, Canada) supplemented with 20 % FBS,
insulin (10 mg/L), glutamine (2 mM) and antibiotics.
CaOV3 cells were cultured in DMEM/F12 (Wisent)
supplemented with 10 % FBS, 2 mM glutamine and
antibiotics. Acellular ascites fractions were obtained at
the time of initial cytoreductive surgery from women with
advanced serous ovarian carcinomas. Samples were
supplied by the Banque de tissus et de données cliniques
et biologiques sur les cancers gynécologiques et du sein de
Sherbrooke as part of the Banque de tissus et de données
du Réseau de Recherche en Cancer des Fonds de
Recherche du Québec en Santé (FRQS) affiliated to the
Canadian Tumor Repository Network (CTRNet). HRP-
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conjugated anti-mouse and rabbit antibodies and anti-FAK
antibody were purchased from Cell Signaling Technology
(Danvers, MA). Anti-phospho FAK and anti-phospho Pyl2
were from Thermo Fisher (Waltham, MA). Anti-Pyk2
and anti-Tubulin were purchased from Sigma-Aldrich
(Oakville, ON). CCL18 and CCL18 neutralizing antibody
were from RnD Systems (Minneapolis, MN). Plasmid
pCMV6-ENTRY-PTK2B was obtained from Origene
(Rockville, MD).
Quantitative real time PCR
Total RNA was extracted from CaOV3 cells using TRIzol
reagent (Life Technologies) according to the manufac-
turer’s protocol and subjected to reverse transcription
(RT) with oligodT from Promega (Madison, WI) and
MMULV reverse transcriptase enzyme. RNA concentra-
tions were quantified by measurement of absorbance at
260 nm. The integrity of the cDNA was assessed with the
Taqman gene expression assays (Life Technologies), done
on RPLPO housekeeping gene. Each sample was normal-
ized to the housekeeping gene levels. Primers for Pyk2 are
as follow: Forward: 5′-CGGACTGATGACCTGGTGTA-
3′, Reversed: 5′-TTCTTCACCACCACCACGTA-3′. Cycle
conditions for all PCRs were as follow: an initial incubation
of 2 min at 95 °C followed by 35 cycles at 94 °C 30 s, 55 °C
30 s, 72 °C 60 s. The 2-ΔΔCt method was used to calculate
the relative levels of specific mRNA.
Migration assay
Cells (5 × 103) were suspended in 500 μl FBS and
hormone-free DMEM/F12 and were seeded in the top
chamber of monolayer-coated polyethylene terephthalate
membranes cell culture inserts (24-wells insert, 8 μm
pore size). The bottom chamber contained 0.75 ml
DMEM/F12 supplemented with 10 % fetal bovine serum,
10 % ascites, or CCL18. The cells were incubated for
16–20 h, and cells that did not migrate through the
membrane were removed by scraping with a cotton
swab. Cells that migrated through the membrane were
fixed with ice cold methanol for 10 min and stained with
a 0.5 % crystal violet, 20 % (v/v) hematoxylin solution
in ethanol for 15 min. After several washes in PBS, mem-
branes were allowed to dry before being mounted on a
glass slide. Ten random fields were counted at × 100
magnification.
ELISA measurements
Cytokine levels in peritoneal fluid samples were deter-
mined by ELISA using the commercially available hu-
man Quantikine kits from R&D Systems (Minneapolis,
MN). The assays were performed in duplicate according
to the manufacturer’s protocols. The detection threshold
was 1.1 ng/ml for CCL18. The intra-assay variability was
3.2–3.7 % for CCL18. The inter-assay variability was
3.5 %. All samples were examined in duplicate and the
median values were used for statistical analysis.
Western blot analysis
Cells were harvested and washed with ice-cold PBS.
Whole cell extracts were prepared in lysing buffer (glycerol
10 %, Triton X-100 1 %, TRIS 10 mM pH 7.4, NaCl
100 mM, EGTA 1 mM, EDTA 1 mM, SDS 0.1 %) contain-
ing protease inhibitors (0.1 mM AEBSF, 5 μg/ml pepstatin,
0.5 μg/ml leupeptin and 2 μg/ml aprotinin) and phosphat-
ase inhibitors (Na4P2O7 20 mM, NaF 1 mM, Na3VO4
2 mM). Proteins were separated by 12 % SDS-PAGE gels.
Proteins were transferred to PVDF membranes (Roche,
Laval, Québec, Canada) by electroblotting, and immuno-
blot analysis was performed as previously described [13].
All primary antibodies were incubated overnight at 4 °C in
5 % fat-free milk. Proteins were visualized by enhanced
chemiluminescence (GE Healthcare, Baie d’Urfé, Québec,
Canada).
siRNA transfections
The Fluorescein-labeled Luciferase GL2 duplex or a non-
target (scrambled) siRNAs used as a control were from
Dharmacon Research (Lafayette, CO). Cells (6 × 104) were
seeded in 6-well plates and allowed to adhere for 24 h.
Cells (50 % confluent) were transfected with a mixture
containing Lipofectamine 2000™ (Life Technologies), opti-
MEM (Life Technologies) and siRNA (10 μM). The siR-
NAs/Lipofectamine complex was then added to the media
of 6-well plates containing cells. Cells were incubated for
4–6 h at 37 °C in a CO2 incubator and medium containing
FBS was then added. The Pyk2 smart pool siRNAs was
from GE Health Care (Ottawa, Canada).
Immunohistochemistry staining
TMAs were acquired from the Pan-canadian platform
for the development of biomarker-driven subtype spe-
cific management of ovarian carcinoma (COEUR study).
Slides were deparaffinized in citrate buffer containing
0.05 % Tween at 97 °C for 20 min, washed with PBS and
incubated with 3 % peroxide. After treatment, slides
were submerged in a citrate buffer (0.01 M citric acid,
pH 6.0) for 15 min, and incubated with a protein block-
ing serum-free reagent (Dako Canada). The TMAs were
stained by an immunoperoxidase method using an auto-
mated tissue immunostainer (Dako Canada) with DAB-
chromogen. The TMAs were counter stained with
hematoxilin and slides were scanned using HAMAMA-
TSU Nanozoomer (Boston, MA) and each tissue section
were scored according to the staining intensity where
negative staining = 0, low staining = 1+, moderate stain-
ing = 2+ and high staining = 3+. Two separate TMAs
containing different section of the same tumor were
scored and the mean intensity was used.
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Statistical analysis
Statistical comparisons between two groups were per-
formed using the Mann-Whitney or Student’s t-test. The
correlation between phospho-FAK and phospho-Pyk2 ex-
pression in tissue section was determined by the Pearson’s
correlation test. Statistical differences in PFS or overall sur-
vival were determined by the log-rank test, and Kaplan-
Meier survival curves were made. PFS was defined as the
interval between the date of the initial debulking surgery
and the time of disease progression or the last date of
follow up. Statistical significance was indicated by P < 0.05.
Results
Levels of CCL18 in malignant ascites from ovarian cancer
patients
A previous study has shown that levels of CCL18 in
ascites from patients with OC were significantly higher
compared to those with none ovarian carcinomas [21]. To
extent these data, we measured the CCL18 levels in ascites
of patients with serous OC (n = 53) and in the peritoneal
fluids of patients with benign gynecological conditions
(n = 24). CCL18 levels were significantly higher in OC as-
cites compared to benign fluids with median concentra-
tions of 21.4 ng/ml and 1.5 ng/ml respectively (P = 0.0023)
(Fig. 1). These data raise the possibility that CCL18 in as-
cites could play a role in OC progression.
We next correlated the levels of CCL18 in ascites with
the progression-free survival (PFS). Women were separated
in CCL18 high and low groups based on the CCL18
median level in ascites. A Kaplan-Meier progression-
free survival curve showed that, although it did not
reach statistical significance, women with low CCL18
(<21.4 ng/ml) had a tendency for longer PFS with a me-
dian of 21 months compared to 18 months for those with
high CCL18 (>21.7 ng/ml) level in ascites (log rank test,
P = 0.31) (Fig. 1b).
Malignant ascites and CCL18 stimulate the migration of
ovarian cancer cells
We first examined the effect of serous OC ascites on the
migration of OC cells CaOV3 and OVCAR3, two com-
monly used OC cell line models. CaOV3 cells were ex-
posed to different ascites (10 % v/v) obtained from
patients with advanced serous OC and migration was
determined using Transwell chambers. The concentra-
tion of ascites used in this study was based on previous
studies demonstrating a biological effect of ascites on
OC cells at this concentration [13–15]. Although the
magnitude of the effect on cell migration was variable,
all 6 OC ascites samples significantly enhanced migra-
tion of CaOV3 cells (Fig. 2a). Migration was also en-
hanced by serous OC ascites when tested with OVCAR3
cells (Fig. 2b). Unlike CaOV3 cells, OVCAR3 cells are
non-invasive in Boyden chambers and non-motile on
plastic [29]. In line with the low motility potential of
OVCAR3 cells, the magnitude of ascites-mediated mi-
gration was lower in these cells relative to CaOV3. We
next found that CCL18 dose-dependently induced the
migration of CaOV3 and OVCAR3 cells (Fig. 2c and d).
The range of CCL18 concentrations selected were within
the range of those found in OC ascites. Furthermore,
there was a positive correlation between the levels of
CCL18 found in serous OC ascites and the ability of these
ascites to induce the migration of CaOV3 cells (r = 0.637,
P < 0.01) (Fig. 2e). These data suggest that CCL18 and ser-
ous OC ascites enhance OC cell migration and that
CCL18 may have a role in ascites-induced cell migration.
To further define the role of CCL18 in ascites-induced
cell migration, we examined the effect of a CCL18-
blocking antibody. As shown in Fig. 2f, the ascites-induced
migration of OC cells was significantly inhibited by the
preincubation of ascites with the CCL18-blocking anti-



















Fig. 1 Presence of CCL18 in ovarian cancer ascites. a The concentration of CCL18 in advanced serous ovarian cancer ascites (n = 54) and benign
fluids (n = 24) was determined by ELISA. Box plot representing levels of CCL18. b Kaplan-Meier curve of ascites CCL18 levels. The median CCL18
level (21.7 ng/ml) was taken as the cutoff point
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only achieved a partial (43 to 57 %) inhibition of ascites-
induced migration suggesting the possible contribution of
other factors in this process. Nonetheless, our data suggest
that CCL18 is an important factor in ascites that promotes
the migration of OC cells. The difference in the magnitude
of ascites-induced effect on migration between CaOV3 and
OVCAR3 cells was not related the CCL18 receptor expres-
sion as PITPNM3 levels were found to be similar in both
cell lines (Fig. 2g).
Ascites and CCL18 induce activation of Pyk2 in ovarian
cancer cells
Previous studies have shown that CCL18 exerts its effect
on cell migration through Pyk2 activation in breast can-
cer cells [19]. To investigate whether OC ascites affect
Pyk2 activation or expression, immunoblots were per-
formed at different time points in CaOV3 and OVCAR3
cells in the presence of OVC509 serous ascites. As
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Fig. 2 Ovarian cancer ascites and CCL18 enhance the migration of tumor cells. The migration of ovarian cancer CaOV3 cells (a) and OVCAR3 cells
(b) was evaluated at 24 h using Boyden chambers with either serum-free medium (control) or different ovarian cancer ascites as chemoattractants.
CaOV3 cells (c) and OVCAR3 cells (d) were treated with 0–50 ng/ml CCL18 for 24 h and migration was determined. Results shown are representative
of three independent experiments and data are expressed as fold increased relative to control. P values are indicated relative to controls. e CCL18 levels
in ascites were correlated with the ability of ascites to stimulate CaOV3 cell migration. The correlation coefficient (r) was determined by Pearson’s
correlation coefficient test. f Incubation of ascites (OVC439 and OVC551) with CCL18-blocking antibody (20 μg/ml) reduces the migration
expressed as the number of migrated cells in CaOV3 and OVCAR3 cells. Values as mean ± SEM and represent three independent experiments:
*P < 0.001. g Immunoblot analysis of PITPNM3 expression in CaOV3 and OVCAR3 cells
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dependent manner by the addition ascites to the culture
medium of CaOV3 and OVCAR3 cells. The activation of
Pyk2 by OC ascites in CaOV3 and OVCAR3 cells was
confirmed using two other ascites samples, OVC439 and
OVC551 (Fig. 3b). We next determine whether the ex-
pression of Pyk2 was affected by OC ascites. As shown
in Fig. 3, the expression of Pyk2 protein was upregulated
when CaOV3 and OVCAR3 cells were incubated with
different serous OC ascites. To determine whether Pyk2
expression changes were the result of increased tran-
scription or altered protein stability, we examined Pyk2
mRNA levels in CaOV3 cells at 2 and 6 h following ex-
posure to OVC439 ascites. Pyk2 mRNA levels, as deter-
mined by quantitative real time PCR, were upregulated
by at least two-fold (Fig. 3d). Treatment of CaOV3 and
OVCAR3 cell lines with CCL18 (0–50 ng/ml) for 90 min
induced the activation of Pyk2 in a dose-dependent
manner to a level similar to that found with OC ascites
(Fig. 3e). These data demonstrate that OC ascites and
CCL18 induce Pyk2 activation in OC cells.
Pyk2 activation in advanced serous ovarian cancer
Pyk2 is a non-receptor tyrosine kinase structurally re-
lated to FAK, which integrate growth factor and integrin
signals to promote cell migration [30, 31]. Tissue micro-
arrays from women with high grade advanced serous
OC were immunohistochemically stained for pPyk2 and
pFAK (Fig. 4a). Previous reports demonstrated that Pyk2
is localized in the cytoplasm and the perinuclear region
[32, 33]. In stress-induced tumor cells, Pyk2 can accumu-
late in nucleus [32]. As shown in Fig. 4a, pPyk2 was local-
ized to the peripheral adhesive region as well as in the
cytoplasm. Very few nucleus stained positive for pPyk2. In
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Fig. 3 Ovarian cancer ascites and CCL18 induce the phosphorylation of Pyk2. a Serous ovarian cancer ascites OVC509 induce a rapid phosphorylation
of Pyk2 at tyr402 in OVCAR3 and CaOV3 cells. Cells were incubated in serum-free media for 24 h, the media was change and OVC509 ascites (10 % v/v)
was added for up to 90 min. Densitometric quantification of phosphorylated Pyk2 normalized to total Pyk2. The fold increase of phosphorylated Pyk2
is indicated at the bottom of pPyk2 panels. b The stimulation of Pyk2 phosphorylation was confirmed in CaOV3 and OVCAR3 cells using the additional
serous ovarian cancer ascites, OVC439 and OVC551. c Immunoblot for total Pyk2 expression from CaOV3 and OVCAR3 lysates obtained at 24 h
following the addition of ovarian cancer ascites. d Real-time PCR analysis of Pyk2 transcript levels at 2 h and 6 h following the addition
of OVC439 ascites. Results were standardized using primers of the housekeeping gene RPLPO. Results are expressed as fold change relative to basal
levels observed in cells incubated in the absence of ascites. e CaOV3 and OVCAR3 cells were treated with increasing concentration of
CCL18 (0–50 ng/ml) or ascites for 90 min. Immunoblot were obtained to assess the phosphorylation of Pyk2
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pPyk2 negative, 37 (44 %) were weakly positive (score 1+),
26 (31 %) were moderately positive (score 2+) and the
remaining 6 (7.1 %) were intensively positive (score 3+).
Phosphorylated FAK was expressed in 100 % of the
high grade serous OC. Among these cases, 5 (6 %) were
weakly positive (score 1+), 33 (39.3 %) were moderately
positive (score 2+) and 46 (54.7 %) were intensively
positive (score 3+). There was no correlation between
the intensity of pPyk2 and pFAK expression in OC tissues
(r = 0.080).
We next examined the correlation of pPyk2 expression
with progression-free survival and overall survival. Women
with pPyk2 positive tumors had a significantly shorter
progression-free survival than women with pPyk2 negative
tumors (Fig. 4b). The median progression-free survival of
women with pPyk2 positive tumors was 16 months com-
pared to >80 months for women with pPyk2 negative tu-
mors (Log-rank test, P = 0.032). We observed a tendency
towards decreased overall survival in women with pPyk2
positive tumors with a median overall survival of 46 months
compared to 59 months for women with pPyk2 negative
tumors (Log-rank test, P = 0.087) (Fig. 4b).
Pyk2 positively regulates ascites-induced ovarian cancer
cell migration
To examine the role of Pyk2 in OC cell migration, we
enforced the overexpression of Pyk2 in OVCAR3 and
CaOV3 cells. As shown in Fig. 5a, the expression of
Pyk2 was significantly upregulated by the transfection of
the Pyk2 vector in OVCAR3 and CaOV3 cells relative to
empty vector-transfected cells. Enforced expression of
Pyk2 significantly stimulated the migration of OVCAR3
and CaVO3 cells (Fig. 5, P < 0.001). Conversely, siRNA-
mediated attenuation of Pyk2 protein expression in CaOV3
and OVCAR3 cells significantly decreased cell migration
(Fig. 5b, P < 0.001). All together, these data suggest that
Pyk2 plays an important role in OC cell migration.
Pyk2 downregulation inhibits CCL18 and ascites-induced
cell migration
To assess the role of CCL18 in ascites in cell migration
activity, we examined the effect of downregulating Pyk2
expression. As shown in Fig. 6a, siRNA-mediated down-
regulation of Pyk2 protein markedly inhibited the migra-





Fig. 4 Activation of Pyk2 in advanced serous ovarian cancer. A tissue microarray containing sections of 120 tumors from women with advanced
serous ovarian cancer was stained with antibodies specific for pPyk2 and pFAK. Tumors were scored as negative, weakly positive (1+), moderately
positive (2+) or intensively positive (3+). a Representative images of immunoperoxidase-stained tissue for pFAK and pPyk2 demonstrating either
negative staining (0), weak (1+), moderate (2+) and intensive staining (3+). None of the tumors stained negative for pFAK. b Kaplan-Meier curves
for progression-free and overall survival. The graphs show women who had advanced serous ovarian carcinoma with pPyk2 positive tissue staining
and women who had advanced serous ovarian carcinoma with no pPyk2 expression
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and OVC551 from advanced serous OC patients. Down-
regulation of Pyk2 protein was confirmed by immuno-
blot in CaOV3 cell (Fig. 6b).
To confirm the involvement of CCL18 in the induction
of OC cell migration, we examined whether the downreg-
ulation of Pyk2 could block CCL18-induced migration.
As shown in Fig. 6c, the CCL18-induced effect was
significantly inhibited by siRNA-mediated attenuation of
Pyk2 protein expression in both CaOV3 and OVCAR3
cells. These results suggest that CCL18 in ascites may
participate in the induction of migration.
Discussion
Ovarian cancer is a highly metastatic disease characterized
by widespread intraperitoneal dissemination and ascites
formation. Cancer-related inflammation plays an important
role in OC progression [9]. Chemokine production is
associated with chronic inflammation and high levels
are found in ascites from advanced OC [6]. Some
inflammation-related factors in ascites have been
shown to play a pivotal role in pancreatic cancer progres-
sion and metastasis [34]. In the present study, we
show that CCL18, a C-C chemokine mainly secreted by
monocyte-derived cells with M2 phenotype [35], was
present at significantly higher levels in ascites obtained
from women with advanced serous OC compared to
women with benign gynecological conditions. This is con-
sistent with previous data showing high levels of CCL18
in ovarian cancer patients [21, 22]. Although women
with high levels of CCL18 had generally a worse out-
come compared to women with low CCL18 in our
study, the difference did not reach statistical signifi-
cance. This is perhaps not surprising given the complex
nature of OC ascites and the overall outcome is most
likely the results of the combined effect of each individual
factors affecting tumor cell behavior.
Unlike most carcinomas, OC dissemination is primar-
ily mediated by the shedding of tumor cells from the pri-
mary site into peritoneal fluids where they formed free-






























































































































Fig. 5 Pyk2 regulates ovarian cancer cell migration. a Expression of Pyk2 in CaOV3 and OVCAR3 cells promotes cell migration. Cells were stably
transfected to express Pyk2 or empty vector (EV). Immunoblots show the expression of Pyk2 in these cell populations. Cell migration was
assessed. b CaOV3 and OVCAR3 cells were transfected with Pyk2 siRNA or control non-targeted siRNA (NT siRNA). Pyk2 knockdown was confirmed
at 48 h by immunoblot analysis. Cell migration was assessed. Results shown are representative of three independent experiments and data are
expressed as the number of total cells that migrated/10 fields. * indicates P < 0.001 relative to controls
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peritoneal carcinomatosis [36]. Development of pelvic
and peritoneal metastasis involves well-defined critical
steps, including cell exfoliation, resistance to apoptosis,
interaction and adhesion to mesothelial layer, migration
and proliferation [36, 37]. We previously demonstrated
that OC ascites protect tumor cells from apoptosis
through activation of Akt and Erk signaling resulting in
the upregulation of anti-apoptotic proteins Mcl-1 and
cFLIP [13–15]. This study provide the first evidence that
CCL18 in ascites is a factor involved in the stimulation
of tumor cell migration. In accordance with this, we
found a positive correlation between the levels of CCL18
in ascites and its ability to enhance cell migration, and
blocking CCL18 antibodies can inhibit ascites-induced
cell migration. The mechanisms of CCL18 action in-
clude a direct effect on tumor cells via the activation of
Pyk2. This is supported by the following observations.
First, siRNA-mediated downregulation of Pyk2 protein
expression inhibited the migration response to ascites as
well as CCL18-induced migration. Second, the CCL18
levels in ascites were high enough to stimulate the mi-
gration of tumor cells and to activate Pyk2. Third,
enforced expression of Pyk2 in OC cells markedly en-
hanced their migration. Finally, siRNA-mediated down-




































































































































































Fig. 6 Pyk2 inhibition markedly attenuates ascites and CCL18-induced cell migration. a siRNA-mediated downregulation of Pyk2 attenuates
ascites-induced migration of CaOV3 and OVCAR3 cells. Cells were transfected with non-targeted (NT siRNA) or Pyk2 siRNA. After 48 h, cells were
transferred in Boyden chambers. OC ascites (OVC439 or OVC551) were used as chemoattractants in the lower chambers. Cell migration was
measured 24 h later. b Immunoblot of CaOV3 cells transfected with NT or Pyk2 siRNA and probed with Pyk2 antibody. c CaOV3 and OVCAR3 cells
were transfected with non-targeted (NT siRNA) or Pyk2 siRNA. Control corresponds to mock-transfected cells. After 48 h, cells were transferred in
Boyden chambers. CCL18 (50 ng/ml) was used as chemoattractants in the low chambers. Cell migration was measured 24 h later. Results shown
are representative of three independent experiments and data are expressed as fold increased relative to serum-free incubated cells. P values are
indicated relative to mock and NT siRNA-transfected cells
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In the current study, we demonstrated for the first time
that Pyk2 activation in high-grade serous OC was signifi-
cantly associated with decreased progression-free survival
but not with overall survival. In our tissue microarray ana-
lysis of 84 clinical samples derived from patients with ad-
vanced serous ovarian cancer, women with pPyk2 positive
tumors had a 16 months median progression-free survival
compared to >80 months for women with pPyk2 negative
tumors. This is consistent with previous studies demon-
strating an association between Pyk2 expression and
worse outcome in hepatocellular carcinomas [38, 39]. Ex-
pression of pPyk2 was found in nearly 80 % of advanced
serous ovarian cancer patients. It is well established that
epithelial-to-mesenchymal (EMT)-associated processes,
including cell migration, are determinants for metastasis
and therefore poor prognosis. Pyk2 has been reported to
induce EMT [40]. Hence, our findings suggest that Pyk2
could enhance EMTand contribute to ovarian cancer pro-
gression and metastasis resulting in a worse outcome.
Pyk2 integrates ascites signaling to potentiate cell migra-
tion. Specifically, we found that Pyk2 is activated by
CCL18 in a dose-dependent manner and its depletion
leads to substantial inhibition of ascites and CCL18-
mediated cell migration. However, CCL18 may not be the
only factor in ascites capable of activating Pyk2. Epidermal
growht factor (EGF), HER2 and IL-8 receptors have also
been shown to activate Pyk2 [41]. These factors have been
found to be present in ascites and Pyk2 may therefore in-
tegrate signaling from various factors in ascites. This could
explain why the levels of CCL18 alone in ascites were not
correlated with progression-free survival whereas pPyk2
expression was associated with shorter progression-free
survival. Although this would deserve further studies,
pPyk2 could represent a new OC prognostic biomarker.
The present study suggests the importance of CCL18
in ascites-mediated cell migration, but this finding does
not rule out the possible involvement of other factors
from ascites in tumor cell migration. For example, fibro-
nectin, lysophosphatidic acid (LPA), IL-6 and CCL2 have
all been shown to enhance OC migration and these fac-
tors may be present at high level in ascites [42–45]. The
fact that Pyk2 downregulation only partially abrogate
ascites-mediated cell migration is in line with this possi-
biliy and raises the possibility that other factors in ascites
can signal through other signaling pathways to stimulate
cell migration. It is also possible that CCL18 may affect
cell migration through Pyk2-independent signaling path-
ways. For example CCL18 has been shown to promote
metastasis via mTOR and ERK1/2-NF-kB signaling path-
ways [22, 46].
Conclusions
In this study, we investigated the contribution of the
tumor environment in tumor cell migration. CCL18 was
identified as one of the soluble factors responsible for
ascites-induced ovarian cancer cell migration through
activation of Pyk2. Pyk2 activation was clinically associ-
ated with shorter progression-free survival in women
with advanced ovarian cancer. Therefore, CCL18 and
pPyk2 may represent potential therapeutic targets for
OC women.
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